Literature DB >> 1849652

Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus.

R H Scofield1, J B Harley.   

Abstract

The fine specificity of a reference human anti-Ro/SSA autoantibody-containing serum has been analyzed by using sequential overlapping octapeptides from the human 60-kDa Ro/SSA antigen. From preliminary data, the most antigenic octapeptide in the carboxyl-terminal 120 amino acid residues of Ro/SSA shares seven of eight amino acids with the nucleocapsid (N) protein from the Indiana serotype of vesicular stomatitis virus. A sequence comparison of Ro/SSA and N has unexpectedly revealed six small peptides shared by Ro/SSA and N. Fine specificity analysis with 531 octapeptides from the Ro/SSA sequence demonstrates that five of the six shared small peptides are bound by anti-Ro/SSA (P = 0.00017). A more powerful association is not present in 12,476 protein sequences similarly evaluated. In addition, the inclusion of single-residue gaps in Ro/SSA enlarges the sequence similarity of Ro/SSA and N for three of the five small shared antigenic peptides. This additional level of sequence similarity between Ro/SSA and N is unlikely to be the result of chance (P less than 0.0002). While a number of models may explain these data, including independent immune responses to N and Ro/SSA, these results are also consistent with anti-Ro/SSA autoantibodies being the consequence of a specific viral exposure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849652      PMCID: PMC51443          DOI: 10.1073/pnas.88.8.3343

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Viral transcription is necessary and sufficient for vesicular stomatitis virus to inhibit maturation of small nuclear ribonucleoproteins.

Authors:  D E Crone; J D Keene
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

2.  Long-term persistent vesicular stomatitis virus and rabies virus infection of cells in vitro.

Authors:  J J Holland; L P Villarreal; R M Welsh; M B Oldstone; D Kohne; R Lazzarini; E Scolnick
Journal:  J Gen Virol       Date:  1976-11       Impact factor: 3.891

3.  Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles.

Authors:  N J DePolo; C Giachetti; J J Holland
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

4.  N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells.

Authors:  L Puddington; M J Bevan; J K Rose; L Lefrançois
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

Review 5.  Autoantibodies.

Authors:  J B Harley; K K Gaither
Journal:  Rheum Dis Clin North Am       Date:  1988-04       Impact factor: 2.670

6.  Entry pathway of vesicular stomatitis virus into different host cells.

Authors:  F Superti; L Seganti; F M Ruggeri; A Tinari; G Donelli; N Orsi
Journal:  J Gen Virol       Date:  1987-02       Impact factor: 3.891

7.  Sequences of Chandipura virus N and NS genes: evidence for high mutability of the NS gene within vesiculoviruses.

Authors:  P S Masters; A K Banerjee
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

8.  Autoimmune response to the Ro/SSA particle is directed to the human antigen.

Authors:  M Reichlin; M Rader; J B Harley
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

9.  Primary structure of leader RNA and nucleoprotein genes of the rabies genome: segmented homology with VSV.

Authors:  N Tordo; O Poch; A Ermine; G Keith
Journal:  Nucleic Acids Res       Date:  1986-03-25       Impact factor: 16.971

10.  A subset of hY RNAs is associated with erythrocyte Ro ribonucleoproteins.

Authors:  C A O'Brien; J B Harley
Journal:  EMBO J       Date:  1990-11       Impact factor: 11.598

View more
  34 in total

1.  IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60-kD SSA/Ro protein.

Authors:  S Barakat; O Meyer; F Torterotot; P Youinou; J P Briand; M F Kahn; S Muller
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

Review 2.  Molecular mimicry and autoantigens in connective tissue diseases.

Authors:  A C Horsfall
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 3.  Methods of epitope mapping.

Authors:  I Pettersson
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 4.  B-cell epitopes of La and Ro autoantigens.

Authors:  S Whittingham
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 5.  Autoantibodies against small cytoplasmic ribonucleoproteins: the anti-Ro/SS-A and anti-La/SS-B autoimmune response. A review of autoantibody detection, autoantigen composition, autoantibody-disease associations and possible etiologic mechanisms.

Authors:  J F Meilof
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 6.  The role of autoantigens in the induction and maintenance of autoimmunity.

Authors:  P H Plotz
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

7.  Viruses contribute to the development of Sjögren's syndrome.

Authors:  P Youinou; J-O Pers; A Saraux; Y-L Pennec
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 8.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

9.  Epitope mapping of ribonucleoprotein antigens: answers without questions?

Authors:  P J Venables
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

Review 10.  Sjögren's syndrome--study of autoantigens and autoantibodies.

Authors:  John G Routsias; Athanasios G Tzioufas
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.